This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Excaliard Pharmaceuticals, Inc.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Mark Jewell: Innovator in Scar Treatment
Introduction
Mark Jewell is a notable inventor based in Eugene, OR (US). He has made significant contributions to the field of dermatology, particularly in the treatment of keloids and hypertrophic scars. His innovative approach utilizes antisense compounds to target connective tissue growth factor (CTGF), providing new methods for preventing and treating fibrotic lesions.
Latest Patents
Mark Jewell holds 1 patent for his invention titled "Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)." This patent outlines methods for preventing the formation of, or treating, fibrotic lesions, including skin scars. The invention involves administering a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits the expression of proteins involved in fibrosis. Additionally, the patent describes a dosing technique using intradermal threading.
Career Highlights
Mark Jewell is currently associated with Excaliard Pharmaceuticals, Inc., where he continues to develop innovative solutions in the field of scar treatment. His work has the potential to significantly improve the quality of life for individuals suffering from problematic scars.
Collaborations
Mark has collaborated with notable colleagues, including Nicholas M Dean and Lincoln Krochmal, to advance research and development in his field.
Conclusion
Mark Jewell's contributions to the treatment of keloids and hypertrophic scars through innovative methods highlight his role as a leading inventor in dermatological advancements. His work continues to pave the way for new therapeutic options in scar management.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile